China's First Approved KRAS G12C Inhibitor: Innovent Announces the Approval of Dupert® (Fulzerasib) by the National Medical Products Administration of China
SAN FRANCISCO and SUZHOU, China, Aug. 21, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that China's National Medical Products Administration (NMPA) has approved Dupert®（fulzerasib）for the treatment of adult patients with advanced non-small cell lung ...